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Ryanodine receptors (RyRs), intracellular calcium re-
lease channels essential for skeletal and cardiac muscle
contraction, are also expressed in various types of
smooth muscle cells. In particular, recent studies have
suggested that in airway smooth muscle cells (ASMCs)
provoked by spasmogens, stored calcium release by the
cardiac isoform of RyR (RyR2) contributes to the cal-
cium response that leads to airway constriction (bron-
choconstriction). Here we report that mouse ASMCs also
express the skeletal muscle and brain isoforms of RyRs
(RyR1 and RyR3, respectively). In these cells, RyR1 is
localized to the periphery near the cell membrane,
whereas RyR3 is more centrally localized. Moreover,
RyR1 and/or RyR3 in mouse airway smooth muscle also
appear to mediate bronchoconstriction caused by the
muscarinic receptor agonist carbachol. Inhibiting all
RyR isoforms with >200 M ryanodine attenuated the
graded carbachol-induced contractile responses of
mouse bronchial rings and calcium responses of ASMCs
throughout the range of carbachol used (50 nM to >3 M).
In contrast, inhibiting only RyR1 and RyR3 with 25 M
dantrolene attenuated these responses caused by high
(>500 nM) but not by low concentrations of carbachol.
These data suggest that, as the stimulation of musca-
rinic receptor in the airway smooth muscle increases,
RyR1 and/or RyR3 also mediate the calcium response
and thus bronchoconstriction. Our findings provide
new insights into the complex calcium signaling in
ASMCs and suggest that RyRs are potential therapeutic
targets in bronchospastic disorders such as asthma.
The three mammalian isoforms of ryanodine receptors
(RyRs)1 are large homotetrameric ion channels that constitute
one of the two known families of intracellular Ca2 release
channels in eukaryotic cells (1, 2). These channels are so named
because they bind specifically to the plant alkaloid ryanodine
that was used to isolate them (3). RyRs and the other family of
intracellular Ca2 release channels, the inositol 1,4,5-trisphos-
phate receptors (IP3Rs), may co-express in the same cell type
(1, 4). These two families of ion channels mediate many cellular
processes by releasing signaling messenger Ca2 from intra-
cellular stores into cytosolic compartments in response to ex-
tracellular stimuli (1).
The physiological roles and regulatory mechanisms of RyRs
are best characterized in skeletal and cardiac muscles in which
RyRs are essential for muscle contraction (4). RyR1 and RyR2
are the predominant RyR isoforms in skeletal and cardiac
muscles, respectively. In these tissues, RyRs are localized to
specialized regions of sarcoplasmic reticulum (SR) juxtaposing
tubular invaginations of cell membrane known as t-tubules.
During excitation-contraction coupling, depolarization of the
cell membrane causes voltage-sensitive L-type Ca2 channels
in t-tubules to activate nearby RyRs via either direct physical
coupling (in skeletal muscle) (2, 4–6) or an influx of extracel-
lular Ca2 (in cardiac muscle) (2, 4, 7, 8). The latter mechanism
is referred to as Ca2-induced Ca2 release. The massive re-
lease of Ca2 from SR by RyRs then initiates a cascade of
cellular events that result in muscle contraction.
Outside of striated muscles, all three mammalian RyR iso-
forms (including the brain isoform/RyR3) are variably ex-
pressed in both excitable and non-excitable cells (4, 5, 9–11). In
particular, RyRs have been found in various smooth muscle
types (12–17), in which the physiological roles and regulatory
mechanisms of RyRs are not as well understood as in striated
muscles. Previous studies, however, have shown that RyRs in
vascular smooth muscle cells may have a role in modulating
cerebral and pulmonary arterial blood flow in response to
changes in intravascular pressure (18, 19) and oxygen tension
(20, 21), respectively. In addition, RyRs in other smooth muscle
types may mediate uterine contraction (22, 23) and gastroin-
testinal tract peristalsis (24–26).
RyRs have also been found in airway smooth muscle cells
(ASMCs), in which Ca2 mobilization mediated by RyRs may
have a significant role in spasmogen-induced bronchoconstric-
tion (27–30). Airway spasmogens typically induce both Ca2
release from intracellular stores and Ca2 influx in ASMCs (29,
31, 32), which enable Ca2/calmodulin-dependent myosin light
chain kinase to promote cross-bridging of actin and myosin
filaments, thereby effecting airway smooth muscle contraction
(33). Previous studies have established that many airway spas-
mogens such as histamine, endothelin, and muscarinic receptor
agonists increase the concentration of the second messenger
inositol 1,4,5-trisphosphate in ASMCs via activation of G-pro-
teins and phospholipase C (34) The increase in inositol 1,4,5-
trisphosphate level subsequently causes stored Ca2 release by
IP3Rs that is followed by store-operated Ca
2 influx (1, 29, 32).
Analogously, a series of recent studies using airway smooth
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muscles from human, equine, and murine tracheal tissues have
suggested that many airway spasmogens such as histamine,
bradykinin, and muscarinic receptor agonists also increase the
synthesis of the putative RyR agonist cyclic adenosine diphos-
phate ribose (cADPR) from NAD by cADP-ribosyl cyclase(s)
(35–39). In ASMCs, cADPR appears to cause a specific RyR2
accessory protein, FKBP 12.6, to dissociate from RyR2, thereby
provoking RyR2 to release stored Ca2 (37). The effect of
cADPR on RyR2 may be synergized by the initial increase in
cytosolic Ca2 concentration ([Ca2]cyt) (40) mobilized by IP3Rs
and other plasmalemmal Ca2 channels.
Because all three RyR isoforms have been found to be co-
expressed in vascular smooth muscle cells (15, 16), we assessed
whether RyR isoforms other than RyR2 are expressed in
ASMCs and whether these isoforms are also involved in spas-
mogen-induced bronchoconstriction. Here we report that RyR1
and RyR3 are also expressed in the mouse ASMCs. Our immu-
nofluorescence studies indicate that RyR1 and RyR3 are dis-
tributed to different compartments within these cells: RyR1
appears to localize to the periphery near the cell membrane,
whereas RyR3 is centrally localized to the perinuclear region.
Moreover, our studies of mouse ASMCs and bronchial rings
exposed to the prototypic airway spasmogen/muscarinic recep-
tor agonist carbachol indicate that RyR1 and/or RyR3 also
mediate the Ca2 response and thus bronchoconstriction as the
level of muscarinic receptor stimulation increases. Our findings
that suggest different subcellular localizations of RyR isoforms
in ASMCs as well as the involvement of multiple RyR isoforms
in muscarinic receptor agonist-induced Ca2 response provide
new insights into the complex Ca2 signaling in ASMCs.
EXPERIMENTAL PROCEDURES
Materials—Mouse monoclonal anti-RyR1 IgM was obtained from
Upstate (Waltham, MA). Mouse monoclonal anti-RyR2 IgG was ob-
tained from Affinity BioReagents (Golden, CO). A rabbit polyclonal IgG
raised against a 13-amino acid region specific for RyR3 and a C-termi-
nal cysteine (KKRRRGQKVEKPEC) was prepared as described previ-
ously (41). Species-specific fluorescein isothiocyanate-conjugated goat
anti-mouse IgM, fluorescein isothiocyanate-conjugated goat anti-mouse
IgG, and TRITC-conjugated goat anti-rabbit IgG secondary antibodies
were obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA). [3H]Ryanodine was obtained from PerkinElmer Life Sci-
ences. Ca2 indicator Fura-2 acetoxymethyl ester was obtained from
Molecular Probes (Eugene, OR). Cy3-conjugated mouse monoclonal an-
ti-smooth muscle-specific -actin IgG, ryanodine, dantrolene, and all
other reagents were obtained from Sigma-Aldrich Chemical Co., unless
specified otherwise.
Isolation of Mouse Bronchi—Male C57/BL6 mice (age, 11–12 weeks;
25 g) were obtained from the Jackson Laboratory (Bar Harbor, ME).
Each animal was sacrificed after being anesthetized with an intraperi-
toneal injection of sodium pentobarbital (100 mg/kg). The heart and
lungs were then removed en bloc and immersed in modified Krebs
buffer (118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5
mM CaCl2, 25 mM NaHCO3, and 11 mM glucose, pH 7.4), and main
bronchi (second generation) and lobar bronchi (third generation) were
isolated under microscopic dissection. Adventitial layers were then
removed.
Immunoblot Analyses to Detect RyRs in the Mouse Airway and Verify
the Specificities of Individual Anti-RyR Antibodies—Second and third
generation bronchi from eight mice were pooled and homogenized in
a buffer consisting of 320 mM sucrose, 5 mM HEPES, and a protease
inhibitor mixture (Complete Mini; Roche Molecular Biochemicals)
using a hand-held tissue homogenizer. Microsomal fractions enriched
in RyRs were prepared from the homogenate as described previously
(42). Twenty g of microsomal protein samples were separated by
3–8% Tris acetate SDS-PAGE under reducing condition and trans-
ferred onto nitrocellulose membranes. The protein concentrations
were determined using a Bio-Rad DC protein assay kit. The mem-
branes were first blocked with 5% nonfat milk in 0.05% Tween 20/
PBS at 24 °C for 1 h. Following probing with a mouse monoclonal
anti-RyR1 IgM (1 ng/l) or a rabbit polyclonal anti-RyR3 IgG (1:500),
the blots were developed using a Vectastain ABC-AmP Western blot
detection kit (Vector Laboratories, Burlingame, CA). To verify the
specificity of each anti-RyR antibody for the corresponding RyR iso-
form, tissue homogenates from mouse hind leg skeletal muscle (10
g/lane), heart (10 g/lane), and brain (30 g/lane) that express
RyR1, RyR2, and RyR3, respectively (brain also expresses RyR2),
were used in a separate immunoblot analysis.
Isolation of Mouse ASMCs—The isolation of second and third gener-
ation mouse bronchi was performed as described above, except that
modified Krebs buffer and the subsequent buffers used for isolating
ASMCs all passed through 0.22 m Syrfil-MF filters (Whatman) and
contained 1% penicillin, 1% streptomycin, and 1% antimycotic antibi-
otics (Invitrogen). The airways were cut open longitudinally, and the
epithelium was rubbed off gently using a cotton tip. The smooth muscle
layer was then minced in Ca2-reduced (20 M) Hanks’ balanced salt
solution, followed by digestion in Ca2-reduced Hanks’ balanced salt
solution containing 1000 units/ml type II collagenase (Worthington
Biochemical Corp., Lakewood, NJ), 10 units/ml papain, 2 mg/ml bovine
serum albumin, and 1 mM dithiothreitol for 20 min at 37 °C. The
partially digested ASMCs were then centrifuged at 600  g for 1 min,
resuspended in Ca2-free Hanks’ balanced salt solution, and gently
triturated using a long glass pipette until a large number of elongated
cells were observed (43). ASMCs were then centrifuged, collected, and
resuspended in M199 media with 10% fetal bovine serum and 1%
penicillin/streptomycin. These ASMCs were allowed to grow in the
same media over 5–6 days under standard culture conditions before
they were detached from the flask with 0.25% trypsin/1.0 mM EDTA for
subculture. ASMCs after one or two passages were used in subsequent
studies. The homogeneity of ASMCs was assessed using a mouse mono-
clonal anti-smooth muscle-specific -actin IgG (see below).
RT-PCR Analyses of RyR Isoforms in Mouse Airways and ASMCs—
After removing adventitial tissues, second and third generation bronchi
from each animal were pooled and immersed in RNAlater stabilization
solution (Qiagen, Carlsbad, CA) and homogenized using a hand-held
tissue homogenizer. In addition, mouse hind leg skeletal muscle, heart,
and brain tissues that served as positive control tissues for RyR1, RyR2,
and RyR3, respectively, were also homogenized in the same fashion.
Total RNA was extracted using the Qiagen RNeasy Midi kit according
to the manufacturer’s instructions. Similarly, 7–9 day-old cultured
mouse ASMCs (5  105) after one or two passages were first detached
from culture flasks with 0.25% trypsin/1.0 mM EDTA at room temper-
ature for 5 min, centrifuged at 600  g for 10 min, washed with M199
media twice, and preserved in RNAlater solution. After homogeniza-
tion, total RNA was extracted from ASMCs using the Qiagen RNeasy
Mini kit. The RT-PCR protocol used to amplify target sequences for
each mouse RyR isoform and -actin that served as internal control was
described previously (16). The nucleotide sequences and the lengths of
the expected PCR products (in parentheses after each primer pair) for
each primer pair were as follows: RyR1, GAAGGTTCTGGACAAA-
CACGGG (forward) and TCGCTCTTGTTGTAGAATTTGCGG (reverse)
(435 bp); RyR2, GAATCAGTGAGTTACTGGGCATGG (forward) and
CTGGTCTCTGAGTTCTCCAAAAGC (reverse) (658 bp); RyR3, AGAA-
GAGGCCAAAGCAGAGG (forward) and GGAGGCCAACGGTCAGA
(reverse) (269 bp); and -actin, TGTATGCCTCTGGTCGTACCAC (for-
ward) and ACAGAGTACTTGCGCTCAGGAG (reverse) (592 bp). The
RT-PCR products over 35 cycles of amplification were resolved by
electrophoresis in 1% agarose gels, visualized on a UV transilluminator,
digitally photographed, and analyzed using XCAP software (Epix Inc.,
Buffalo Grove, IL). The product ratios of target/-actin were used to
assess the relative expression of each RyR isoform mRNA in the mouse
airway and in cultured ASMCs.
Immunofluorescence Studies of RyRs in Mouse ASMCs—Primary
mouse ASMCs after one passage were cultured in Lab-Tek slide II
system (Nalge Nunc International, Naperville, IL) for 7 days. The cells
were first washed with PBS (pH 7.4) twice and then fixed with 2%
paraformaldehyde in PBS for 15 min at room temperature. After wash-
ing with PBS two more times, the remaining paraformaldehyde was
then quenched with 0.75% glycine in PBS for 30 min (43). Afterward,
the cells were washed with PBS, permeabilized in 0.1% SDS and 0.05%
Triton X-100 in PBS for 15 min, blocked with 10% goat serum in PBS for
30 min, and probed with individual antibody specific for each RyR
isoform in 1% goat serum/PBS for 1 h. The dilutions for each of these
antibodies were 1 ng/l, 10 ng/l, and 1:1000 for anti-RyR1, anti-RyR2,
and anti-RyR3, respectively. After washing with PBS, cells were incu-
bated with the corresponding fluorochrome-labeled secondary antibody
(7.5 ng/l) in 1% goat serum/PBS for 1 h. Before washing and mounting
on Prolong Antifade solution (Molecular Probes), cells were counter-
stained with 4,6-diamidino-2-phenylindole, which stained the nuclei.
In a few experiments, a goat polyclonal anti-RyR3 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) and TRITC-conjugated donkey anti-
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goat IgG were used to confirm the cellular distribution of RyR3 in
ASMCs. Each experiment contained at least one control in which only
the primary antibody was omitted. The homogeneity of ASMCs was
assessed separately in cells that were probed with a Cy3-conjugated
mouse monoclonal anti-smooth muscle-specific -actin IgG and coun-
terstained with 4,6-diamidino-2-phenylindole. The slides were exam-
ined and digitally photographed using an epifluorescent microscope
(Olympus BX60) equipped with UPlanFl 20–100 objectives and a
mercury lamp.
To assess the relative cellular distribution of RyR1 and RyR3 in
mouse ASMCs, in certain studies mouse ASMCs were double-labeled
with both mouse monoclonal anti-RyR1 IgM and rabbit polyclonal anti-
RyR3 IgG. The prepared slides were examined using the epifluorescent
microscope and a Carl Zeiss LSM 510 laser scanning confocal micros-
copy system attached to an Axiovert 100 inverted microscope (Carl
Zeiss, Jena, Germany). Argon and helium/neon lasers provided the
excitation light beams (488 and 543 nm, respectively) for the confocal
microscopy system. The green (fluorescein isothiocyanate) and orange
(TRITC) emissions were filtered (515–540- and 585–615-nm bandpass
filters, respectively), and images (512  512 pixels) obtained with a 63
objective (Plan-Neofluar) were recorded using LSM Image software.
Carbachol-induced Contractile Responses of Isolated Mouse Bron-
chial Rings—Four bronchial rings (inner diameter, 0.5 mm; length,
2 mm) cut from second and third generation bronchi from each
mouse were studied in parallel. Each bronchial ring was mounted
horizontally on two tungsten triangles (diameter of tungsten wire,
100 m) and submerged in Krebs buffer in a thermostatted organ
bath constantly bubbled with a pre-mixed gas consisting of 20% O2,
5% CO2 and balance N2 (44). The temperature in the organ bath was
maintained at 37 °C. The two tungsten triangles (and thus the bron-
chial ring) were suspended between a stainless steel wire hook con-
nected to a Grass FT-03 force displacement transducer (West
Warwick, RI) and a glass hook inside the organ bath that served as an
anchor. An optimal resting tension of 0.3 g was applied to each ring
during the initial equilibration period of 30 min. The bronchial rings
were then constricted stepwise with 50 and 80 mM KCl (final concen-
tration) over 20 min to determine the viability of bronchial rings and
establish references for comparison. Approximately 30 min after re-
moving excess KCl, bronchial rings were treated stepwise with 10 nM
to 3 M cumulative doses of carbachol (3 M carbachol did not
produce higher contractile responses) at 5–8-min intervals that al-
lowed the contractile responses (isometric tensions) of bronchial rings
after each carbachol challenge to reach steady state. In specified
experiments, an inhibitor of RyRs (ryanodine dissolved in Krebs
buffer or dantrolene dissolved in Me2SO) was added to the organ bath
20 min before the stepwise addition of carbachol. In a typical study,
two of the bronchial rings were pre-treated with a RyR inhibitor,
whereas the other two rings that served as concurrent controls were
pre-treated with equal volumes of delivery vehicle. Increases in iso-
metric tension were amplified (Grass DC pre/amplifier model 7DAF)
and recorded digitally (Polyview software; Grass-Telefactor). The in-
creases in steady-state isometric tension of mouse bronchial rings
caused by cumulative doses of carbachol were normalized against
individual ring increases in isometric tensions generated by 80 mM
KCl (higher concentrations of KCl did not cause further constriction
in mouse bronchial rings).
Carbachol-induced Calcium Responses of Mouse ASMCs—Mouse
ASMCs after one or two passages in M199 media containing 10% fetal
bovine serum were grown over 7 days in a culture coverslip/dish
(MatTek, Ashland, MA) designed for live cell imaging. Mouse ASMCs
were first loaded with 5 M Fura-2 acetoxymethyl ester in M199 media
containing 10% fetal bovine serum for 30 min and then washed with
HEPES-buffered Tyrode solution (145 mM NaCl, 2.8 mM KCl, 2 mM
MgSO4, 2 mM CaCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4) three
times to remove excess Ca2 indicator. The culture dish was then placed
onto a stage mounted on an inverted microscope (Nikon Eclipse
TE2000). After pre-treatment with 200 M ryanodine, 25 M dan-
trolene, or the delivery vehicle for 5 min, increased doses of carbachol
(10 nM to 10 M, cumulative concentrations) were introduced to ASMCs
stepwise at 5–7-min intervals. Fluorescence measurements were per-
formed under ambient temperature (21 °C) on small groups of dis-
persed, elongated cells viewed with a Nikon UV-Fluor 40 oil immer-
sion objective (4–5 cells were studied in each experiment). These
ASMCs were excited alternatively at 340 and 380 nm using a Lambda
DG4 filtering system (Sutter Instruments) that provided rapid excita-
tion filter changes. Illumination was provided by a xenon arc lamp.
Emitted fluorescence was filtered by a 490–530-nm bandpass filter and
captured on a Cool SNAP HQ charge-coupled device camera. Video
images were digitized onto a computer and analyzed using MetaMorph/
MetaFluor software (Universal Imaging Corp.). Ratiometric Ca2 im-
ages were generated at 1-s intervals. For each cell, Ca2 responses to
stepwise carbachol challenges were reflected as a change in fluores-
cence ratio (F340/F380) of Fura-2 at steady-state averaged from pixels
within cytoplasmic areas (45). In control experiments without cells,
neither 200 M ryanodine nor 25 M dantrolene had any noticeable
effect on F340/F380 of Fura-2.
Isoform Specificity of the RyR Inhibitor Dantrolene—[3H]Ryanodine
binding to RyRs, which correlates non-linearly with RyR channel activ-
ities (46, 47), was used to assess the effect of dantrolene on each RyR
isoform. Rabbit skeletal muscle and canine cardiac SR vesicles that
served as sources of RyR1 and RyR2 were isolated as previously de-
scribed (46, 48). To obtain RyR3 for this study, crude microsomal
fractions from HEK cells containing heterologously expressed rabbit
RyR3 were prepared as previously described (49).
Unless otherwise indicated, cardiac muscle, skeletal muscle SR ves-
icles (0.2 mg/ml), or microsomal fractions from HEK cells containing the
heterologously expressed RyR3 (0.4 mg/ml) were exposed to various
concentrations of dantrolene (0–50 M) and incubated for 2 h at 37 °C
with 5 nM [3H]ryanodine in media containing 150 mM KCl, 20 mM
imidazole, pH 7.0, 0.3 mM Pefabloc, 30 M leupeptin, 2 mM adenylyl
5-(,-methylene)diphosphonate, 1.5 mM Mg2, 1 M calmodulin, and
0.3–0.4 M free Ca2. Nonspecific binding was determined using a
1000-fold excess of unlabeled ryanodine. Aliquots of the samples were
diluted with 20 volumes of ice-cold water and placed on Whatman GF/B
filters soaked with 2% (w/w) polyethyleneimine. Filters were washed
with three 5-ml volumes of ice-cold 100 mM KCl, 1 mM PIPES (pH 7)
buffer, and the radioactivity remaining on the filters was determined by
liquid scintillation counting to obtain bound [3H]ryanodine (46).
Data Analysis—All results are expressed as means  S.E. Signifi-
cance of differences of data was analyzed with Student’s t test. A p value
of 0.05 was considered statistically significant.
RESULTS
Detection of RyR Isoforms in the Mouse Airway and
ASMCs—In immunoblot studies, RyR1 and RyR3 were detected
in the microsomal fractions isolated from mouse bronchi (Fig.
1A). We also detected RyR2 in immunoblots using a RyR2-
specific antibody; however, no immunofluorescence was detected
in the localization studies (data not shown). The isoform speci-
ficity of anti-RyR1 and anti-RyR3 antibodies was confirmed us-
ing positive control tissues (Fig. 1B). Each of these RyR-isoform
specific antibodies appears to recognize only the corresponding
RyR isoform. The identification of all three RyR isoforms in the
mouse bronchi was corroborated by RT-PCR analyses (Fig. 1C).
Because the airway contains other cell types that may express
RyRs (50), we examined whether all three RyR isoforms are
expressed within mouse ASMCs. In cultured ASMCs, all stained
positive for smooth muscle-specific -actin (Fig. 2A), and mRNAs
for all three RyR isoforms were also detected by RT-PCR (Fig.
1C). Although RyR2 appears to be the most abundantly ex-
pressed RyR isoform in mouse bronchi by RT-PCR (using -actin
as internal controls), RyR1 is more abundantly expressed in
cultured ASMCs than RyR2 and RyR3 (Fig. 1D).
Subcellular Localization of RyR Isoforms in Mouse ASMCs—
To assess the subcellular localization of RyR isoforms, cultured
mouse ASMCs were probed with individual isoform-specific
anti-RyR antibodies used in our immunoblot studies. As shown
in Fig. 2, in mouse ASMCs, RyR1 is distributed more periph-
erally in close proximity to the cell membrane, whereas RyR3 is
distributed more centrally around the nucleus. The perinuclear
distribution of RyR3 in mouse ASMCs was also found in limited
experiments using a different goat polyclonal anti-RyR3 IgG
(Santa Cruz Biotechnology; data not shown). Although the
expression of RyR2 in mouse ASMCs is demonstrated by RT-
PCR (Fig. 1, C and D), RyR2 was not detected in mouse ASMCs
by the immunofluorescence method (data not shown), possibly
due to a lack of efficacy of this particular antibody in immuno-
histochemical studies. Because no other RyR2-specific antibody
is currently available, the distribution of RyR2 in ASMCs re-
mains undefined.
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Ca2 Mobilization by RyRs in Mouse Airway Smooth Muscle
Provoked by Carbachol—We used two complementary methods
to assess the extent that RyRs contribute to Ca2 mobilization
in ASMCs provoked by the prototypic airway spasmogen/mus-
carinic receptor agonist carbachol. We first determined the
carbachol-induced contractile responses of mouse bronchial
rings in the presence or absence of inhibitory concentrations of
ryanodine, which inhibits all three RyR isoforms, but not other
Ca2 channels such as IP3Rs (4, 51). Stepwise additions of 10
nM to 3 M carbachol (cumulative concentrations) caused iso-
lated bronchial rings to develop graded increases in isometric
tension that reached steady state 5 min after each carbachol
challenge (Fig. 3A). The contractile effects of carbachol first
became prominent at 100 nM and reached maximum at 2 M.
In comparison to their concurrent controls, bronchial rings
pre-treated with 200 or 300 M ryanodine developed signifi-
cantly less contractile response to each corresponding dose of
carbachol (Fig. 3, A and B). In complementary studies of cul-
tured mouse ASMCs, the graded Ca2 responses of these cells
to stepwise carbachol challenges, as reflected by the increases
in F340/F380 ratio of Ca
2 indicator Fura-2 at steady state, were
also significantly suppressed by 200 M ryanodine throughout
the entire range of carbachol used (Fig. 3C). Thus, the inhibi-
tory effects of ryanodine on bronchial rings challenged with
carbachol are due to a decrease in Ca2 mobilization by RyRs
in ASMCs.
Inhibition of RyR1 and RyR3 Suppressed the Responses of
Bronchial Rings and ASMCs to High but Not Low Doses of
Carbachol—Our studies of mouse ASMCs and bronchial rings
in the presence or absence of inhibitory concentrations of ry-
anodine (Fig. 3) indicate that Ca2 mobilization by RyRs con-
tributes to muscarinic receptor-mediated bronchoconstriction
in mice as in other animal species (27, 37). Because a previous
study using equine tracheal smooth muscle has implicated
RyR2 in this process (37), but we have also identified RyR1 and
RyR3 in the mouse airway smooth muscle (Figs. 1 and 2), we
used dantrolene, an inhibitor of RyR1 and RyR3, but not of
RyR2 (47), to determine whether RyR1 and/or RyR3 may also
play a role in carbachol-induced responses of mouse ASMCs
and bronchial rings. We first used an indirect assay of RyR
channel activity, the [3H]ryanodine binding assay (46), to con-
firm the reported effects of dantrolene on individual RyR iso-
forms (47) as well as to determine the optimal concentrations of
dantrolene in the subsequent mouse ASMCs and bronchial ring
studies (Fig. 4A). The amounts of [3H]ryanodine bound to skel-
etal muscle and cardiac muscle SR preparations at steady state
correlate non-linearly with the channel activities of RyR1 and
RyR2, respectively (40, 46). Because purifying RyR3 from na-
tive tissues is confounded by the co-expression of other RyR
isoforms in those tissues, microsomal fractions from HEK cells
heterologously expressing only RyR3 were used in this study.
As shown in Fig. 4A, dantrolene suppressed the channel activ-
ities of RyR1 and RyR3 under our in vitro experimental condi-
tions, although the effect of dantrolene on RyR3 was only
modest. The suppressive effects of dantrolene on RyR1 and
RyR3 plateaued at 15 M. In contrast, RyR2 appears to be
insensitive to dantrolene up to 50 M.
The effects of dantrolene on carbachol-induced contractions
of mouse bronchial rings were then assessed. To ensure tissue
penetration of dantrolene that would maximally inhibit RyR1
and RyR3 but not cause untoward effects (Fig. 4A), 25 M
dantrolene was used in these experiments. Unlike the non-
isoform-specific RyR inhibitor ryanodine (Fig. 3, A and B), 25
M dantrolene had no significant inhibitory effect on the con-
tractile responses of mouse bronchial rings challenged with
50–500 nM carbachol (Fig. 4, B and C; 50 M dantrolene also
failed to suppress the contractile responses of 50–500 nM car-
bachol, data not shown). At higher doses of carbachol, however,
the suppressive effects of 25 M dantrolene on mouse bronchial
rings were comparable to those of 200 or 300 M ryanodine (Fig.
3B). Analogously, as compared with the control group, mouse
ASMCs pre-treated with 25 M dantrolene had smaller Ca2
responses only at carbachol concentrations of 500 nM (Fig.
4D). Because dantrolene inhibits the responses of ASMCs and
bronchial rings only when the cumulative doses of carbachol
were 500 nM, RyR1 and/or RyR3 appear to contribute to the
Ca2 mobilization in ASMCs when the level of muscarinic
receptor stimulation is high.
DISCUSSION
Although previous studies using pharmacological agents
have consistently suggested the presence of functional RyRs in
ASMCs from various mammalian species (27, 35, 37, 51), rel-
atively little is known about the expression and physiological
roles of individual RyR isoforms in this type of smooth muscle.
Using RT-PCR, one study identified RyR3 exclusively in hu-
man bronchial ASMCs (51), whereas other studies had found
RyR2 to be the predominant RyR isoform in tracheal smooth
muscle cells using RT-PCR and immunoblot analyses (17, 37)
(low expression of RyR1 and RyR3 was also detected by RT-
PCR (17)). In contrast, our studies indicate that all three RyR
forms are comparably expressed in the mouse airway and in
primary cultured ASMCs (Fig. 1). The co-expression of all three
RyR isoforms in a single smooth muscle cell type has also been
described in various types of murine vascular smooth muscle
cells (14, 16). The discrepancy of RyR expression in ASMCs
between this study and previous studies could be due to a
difference in techniques used and/or variations among different
FIG. 1. Expression of RyR isoforms in mouse bronchi and cul-
tured ASMCs. A, immunoblot studies using anti-RyR1 and anti-RyR3
antibodies indicate that RyR1 and RyR3 are present in the microsomal
fractions isolated from mouse bronchi. B, immunoblot analyses of ho-
mogenates from skeletal muscle (Sk), heart (Car), and brain (Br) that
express RyR1, RyR2, and RyR3, respectively, show the isoform speci-
ficities of anti-RyR1 and anti-RyR3 antibodies. C, RT-PCR analyses
using isoform-specific primers labeled at the bottom show the expres-
sion of three RyR isoforms in mouse bronchi (bron). Mouse skeletal
muscle (skel), heart, and brain were used as positive control tissues for
RyR1, RyR2, and RyR3, respectively. All RyR isoforms are also detected
in cultured mouse ASMCs (Fig. 2A) by RT-PCR. D, semiquantitative
analysis of individual RyR isoform expression in mouse bronchi () and
in cultured ASMCs (f) using -actin as internal controls (n  3 inde-
pendent experiments).
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mammalian species studied. To detect the relatively low con-
centrations of RyRs in the airway, we used microsomal prepa-
rations enriched in RyRs (42) isolated from mouse bronchi in
our immunoblot studies. Our studies of rat airways using RT-
PCR and immunoblot analyses also indicate that all three RyR
isoforms are expressed in rat bronchi,2 thus it appears that all
three RyR isoforms are expressed in the murine airway.
More importantly, the results from our studies of mouse
ASMCs and bronchial rings add to an emerging body of data
that supports a significant role for RyRs in Ca2 signaling in
various smooth muscle types (16, 21, 25, 30). These data may
eventually modify the prevailing view that IP3Rs are the main
intracellular Ca2 release channel family mediating Ca2 sig-
naling in smooth muscle cells in response to external stimuli.
As in the case of muscarinic receptor-mediated bronchocon-
striction, the type of airway constriction most extensively stud-
ied as well as the most relevant (52, 53), stored Ca2 release by
IP3Rs has long been thought to be the dominant cellular proc-
ess that results in an increase in [Ca2]cyt and thus broncho-
constriction (34, 54, 55). Our data as well as results of other
groups (30, 35–37), however, suggest that RyRs also contribute
significantly to the overall Ca2 responses of ASMCs stimu-
lated with muscarinic receptor agonists. Depending on the dose
of carbachol, inhibiting RyRs but not IP3Rs with ryanodine
suppressed 40–60% of carbachol-induced responses of
ASMCs and bronchial rings (Fig. 3). The roles of IP3Rs and
RyRs in airway spasmogen-induced Ca2 mobilization, how-
ever, need not be mutually exclusive: because RyRs are sensi-
tive to Ca2 activation (i.e. Ca2-induced Ca2 release) (4, 5),
Ca2 mobilization mediated by RyRs in spasmogen-provoked
ASMCs may be a downstream signaling event after the initial
Ca2 release by IP3Rs (30, 37). In the case of RyR2 in ASMCs,2 W. Du and J. P. Eu, unpublished data.
FIG. 2. Subcellular localization of RyR isoforms in mouse ASMCs. A, the purity of mouse ASMCs was assessed using a Cy3-conjugated
mouse monoclonal anti-smooth muscle-specific -actin IgG that stained the cytoplasm of ASMCs orange. B, mouse ASMCs were probed with
anti-RyR1 or anti-RyR3 antibody as indicated. Control was probed with a combination of fluorescent secondary antibodies. Nuclei are stained blue
with 4,6-diamidino-2-phenylindole stain. C, an epifluorescence image of a mouse ASMC double-labeled with mouse monoclonal anti-RyR1 IgM and
rabbit polyclonal anti-RyR3 IgG (left panel) also suggests the peripheral distribution (arrow) of RyR1 (green) and the perinuclear distribution of
RyR3 (orange). A confocal microscopy image (right panel) of a similarly labeled ASMC (optical slice, 0.5 m).
FIG. 3. Effects of ryanodine on carba-
chol-induced contractile responses of
mouse bronchial rings and Ca2 re-
sponses of ASMCs. A, representative
traces of mouse bronchial rings respond-
ing to increased doses of carbachol with-
out (left panel) or with (right panel) pre-
treatment with ryanodine. Increased
doses of carbachol (cumulative concentra-
tions, in M) were added to the organ
baths as indicated (arrows). Vertical bars
indicate the contractile responses of indi-
vidual bronchial rings to 80 mM KCl ob-
tained prior to the addition of ryanodine
and carbachol. B, the increases in steady-
state isometric tension of mouse bronchial
rings (normalized to 80 mM KCl response)
caused by 10 nM to 3 M carbachol were
significantly attenuated by pre-treatment
with 200 M ryanodine (black bars, n  10)
or 300 M ryanodine (shaded bars, n  6)
as compared with concurrent controls
(white bars, n  14). *, p  0.01 versus
groups pre-treated with ryanodine. C, Ca2
responses of mouse ASMCs at steady state,
as reflected by the changes in the fluores-
cence ratio (F340/F380) of Ca
2 indicator
Fura-2, to increased doses of carbachol (50
nM to 10 M, cumulative concentrations) in
the presence (f; n  13 cells) or absence
(; n  15 cells) of 200 M ryanodine. *,
p  0.01 versus 200 M ryanodine group.
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this process may be further assisted by an increase in synthesis
of the putative endogenous RyR2 agonist cADPR (37) following
muscarinic receptor stimulation (Fig. 5). The signaling path-
ways by which individual RyR isoforms are activated in ASMCs
stimulated with spasmogens will require additional studies.
Our immunofluorescence studies of RyR isoforms provide
additional insights into the complex Ca2 signaling in ASMCs.
Although we were unable to determine the subcellular local-
ization of RyR2 in ASMCs, our results demonstrate for the first
time the different subcellular localizations of RyR1 and RyR3
in ASMCs (and to our knowledge, for the first time in any
smooth muscle cell type). RyR1 in ASMCs appears to be dis-
tributed peripherally near the cell membrane, whereas RyR3 is
distributed more centrally around the nucleus (Fig. 2). Our
findings complement the results of an immunoelectron micros-
copy study that showed RyRs are distinctly localized to both
central and peripheral SR elements in vas deferens smooth
muscle cells (14). Thus, the distinct subcellular localizations of
different RyR isoforms as seen in ASMCs could also be present
in other smooth muscle cell types.
The peripheral distribution of RyR1 in ASMCs suggests po-
tential functionalcouplingsbetweenRyR1andotherplasmalem-
mal Ca2 channels in mediating Ca2 mobilization: 1) RyR1
could release stored Ca2 in response to an activation of volt-
age-sensitive L-type Ca2 channels (4); 2) the potential prox-
imity of RyR1 and other plasmalemmal Ca2 channels raises
FIG. 5. Potential pathways of Ca2 mobilization mediated by
RyRs in ASMCs following muscarinic receptor stimulation.
RyRs, including RyR3 (which is not shown), may be activated by an
initial increase in [Ca2]cyt (from stored Ca
2 release via the G-protein-
phospholipase C-IP3R pathway or Ca
2 influx via plasmalemmal Ca2
channels) following the binding of an agonist (carbachol) to the type 3
muscarinic receptors (M3) of ASMCs (54). RyR2 may be activated first
in ASMCs because it is most sensitive to Ca2-induced Ca2 release. In
addition, muscarinic receptor agonists can also causes cADP-ribosyl
cyclase(s) such as CD38 (39) to covert NAD to cADPR, which then
provokes RyR2 (37) to release stored Ca2. Because RyR1 is localized to
the periphery of ASMCs, RyR1 may be functionally coupled to plas-
malemmal ion channels such as L-type Ca2 channels. A “bi-directional
signaling” between the two Ca2 channels may promote both Ca2
release by RyR1 and Ca2 influx via the L-type Ca2 channel as has
been described in skeletal muscle (56).
FIG. 4. Specificity of dantrolene and its effects on carbachol-induced responses of mouse bronchial rings and ASMCs. A, effects of
different concentrations of dantrolene (white bars, control; black bars, 1 M; shaded bars, 15 M; and dark gray bars, 50 M; n  4–7 experiments)
on [3H]ryanodine binding to the indicated individual RyR isoform were determined as described under “Experimental Procedures.” *, p  0.05
versus control group. B, typical traces of mouse bronchial rings responding to increased doses of carbachol after pre-treatment with 25 M
dantrolene (right panel) or with an equal volume of delivery vehicle (Me2SO). Vertical bars indicate the contractile responses of individual bronchial
rings to 80 mM KCl. C, as compared with concurrent controls (white bars, n  20), the steady-state isometric tensions of mouse bronchial rings
pre-treated with 25 M dantrolene (black bars, n  19) are significantly lower only when the cumulative concentrations of carbachol are 500 nM.
*, p  0.01 versus 25 M dantrolene groups. D, graded Ca2 responses of mouse ASMCs to a range of carbachol (50 nM to 10 M) pre-treated with
25 M dantrolene (black bars, n  14) or delivery vehicle (white bars, n  18). *, p  0.01 versus 25 M dantrolene group.
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the possibility of a retrograde activation of the L-type Ca2
channels by RyR, as has been found in skeletal myocytes (56)
and neurons (57); and 3) RyR1 could also be involved in stored-
operated Ca2 influx induced by the depletion of RyR-gated
intracellular Ca2 stores of ASMCs (29). In addition, in other
smooth muscle cell types such as rat cerebral arterial smooth
muscle cells, localized Ca2 release by RyRs known as Ca2
sparks can modulate other Ca2-sensitive plasmalemmal ion
channels such as Cl	 or large conductance K channels,
thereby altering cell membrane potential and Ca2 influx via
voltage-sensitive L-type Ca2 channels (18, 19). Inhibition of
RyR1 in this scenario, however, should enhance rather than
suppress Ca2 mobilization. This is not supported by our stud-
ies using dantrolene (Fig. 4, B	D). We have attempted to
determine the importance of Ca2 influx in Ca2 mobilization
mediated by RyRs. However, both mouse ASMCs and isolated
bronchial rings quickly lost their carbachol-induced responses
in the absence of extracellular Ca2 (data not shown). Thus, to
determine whether Ca2 mobilization mediated by RyR1 in
mouse ASMCs involves Ca2 influx will require direct meas-
urements of membrane potential and Ca2 currents across the
cell membrane.
The results of our studies using dantrolene, which has no
inhibitory effect on RyR2 (47) (also see Fig. 4A), suggest that
Ca2 mobilization and thus bronchoconstriction mediated by
RyR1 and/or RyR3 in the mouse airway smooth muscle become
more prominent as the intensity of muscarinic receptor stimu-
lation increases (Fig. 4, B	D). Because a previous study of
human airway smooth muscle that expressed RyR3 exclusively
did not find a role for RyR in muscarinic receptor-mediated
responses (51), RyR1 could be the main RyR isoform contrib-
uting to the Ca2 mobilization in ASMCs as the intensity of
muscarinic receptor stimulation increases. Because mice defi-
cient in RyR3 are viable, unlike their counterparts deficient in
RyR1 or RyR2, this possibility could be tested in future studies.
Because dantrolene, unlike ryanodine, did not inhibit the
carbachol-induced responses of ASMCs and bronchial rings at
lower doses of carbachol (Fig. 4, B and C), RyR2 could be the
RyR isoform that mobilizes Ca2 in ASMCs provoked by low
concentrations of muscarinic receptor agonists. One possibility
for this observation is that RyR2 is the RyR isoform most
sensitive to Ca2-induced Ca2 release (4). Thus, RyR1 and/or
RyR3 are only activated as the higher intensity of muscarinic
receptor stimulation causes further increases in [Ca2]cyt. The
other possibility is that only RyR2 is sensitive to the putative
endogenous RyR2 agonist cADPR, whose synthesis is increased
in spasmogen-provoked ASMCs (37) (Fig. 5). The latter expla-
nation is supported by a recent study that found, when com-
pared with the Ca2 responses of ASMCs from wild-type mice,
the Ca2 responses of ASMCs from mice lacking an enzyme
critical for synthesis of cADPR in the airway were more atten-
uated when muscarinic receptor stimulation was relatively low
(39). Additional experiments will be needed to study the poten-
tial sequential activations of different RyR isoforms in ASMCs.
However, because neither RyR2-specific inhibitors nor RyR2-
deficient mice are available, further understanding of distinct
roles of individual RyR isoforms in ASMCs as well as in other
smooth muscle cell types will likely require using gene-silenc-
ing techniques. The gene-silencing approach may also be used
to study subcellular Ca2 signaling mediated by RyR1 and
RyR3 in ASMCs because there is no inhibitor that selectively
inhibits RyR1 or RyR3.
Our studies of RyR isoforms in mouse ASMCs provide new
insight into the complex Ca2 signaling in these cells. In
addition to the ensemble of Ca2 channels that have already
been shown to mediate the contractile responses of airways
(32, 54, 58), our data, along with results from other groups,
suggest that Ca2 mobilization by RyRs is also important in
bronchoconstriction. RyRs thus may be exploited as thera-
peutic targets in respiratory disorders characterized by ex-
cessive bronchoconstriction.
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